<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Manqiang</forename><surname>Sun</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Dongfang hospital</orgName>
								<orgName type="department" key="dep2">Fengtai District</orgName>
								<orgName type="institution">Beijing University of Chinese Medicine</orgName>
								<address>
									<addrLine>No.6 Community 1 Fangxingyuan</addrLine>
									<postCode>100071</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Tian</forename><surname>Zhou</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Dongfang hospital</orgName>
								<orgName type="department" key="dep2">Fengtai District</orgName>
								<orgName type="institution">Beijing University of Chinese Medicine</orgName>
								<address>
									<addrLine>No.6 Community 1 Fangxingyuan</addrLine>
									<postCode>100071</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MM</roleName><forename type="first">Xueni</forename><surname>Fang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Dongfang hospital</orgName>
								<orgName type="department" key="dep2">Fengtai District</orgName>
								<orgName type="institution">Beijing University of Chinese Medicine</orgName>
								<address>
									<addrLine>No.6 Community 1 Fangxingyuan</addrLine>
									<postCode>100071</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MM</roleName><forename type="first">Dan</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Dongfang hospital</orgName>
								<orgName type="department" key="dep2">Fengtai District</orgName>
								<orgName type="institution">Beijing University of Chinese Medicine</orgName>
								<address>
									<addrLine>No.6 Community 1 Fangxingyuan</addrLine>
									<postCode>100071</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MM</roleName><forename type="first">Haoyue</forename><surname>Pang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Dongfang hospital</orgName>
								<orgName type="department" key="dep2">Fengtai District</orgName>
								<orgName type="institution">Beijing University of Chinese Medicine</orgName>
								<address>
									<addrLine>No.6 Community 1 Fangxingyuan</addrLine>
									<postCode>100071</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MM</roleName><forename type="first">Yu</forename><surname>Chen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Dongfang hospital</orgName>
								<orgName type="department" key="dep2">Fengtai District</orgName>
								<orgName type="institution">Beijing University of Chinese Medicine</orgName>
								<address>
									<addrLine>No.6 Community 1 Fangxingyuan</addrLine>
									<postCode>100071</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>MD</roleName><forename type="first">Kaiwen</forename><surname>Hu</surname></persName>
							<email>kaiwenh@163.com</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Dongfang hospital</orgName>
								<orgName type="department" key="dep2">Fengtai District</orgName>
								<orgName type="institution">Beijing University of Chinese Medicine</orgName>
								<address>
									<addrLine>No.6 Community 1 Fangxingyuan</addrLine>
									<postCode>100071</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Dongfang hospital</orgName>
								<orgName type="department" key="dep2">Fengtai District</orgName>
								<orgName type="institution">Beijing University of Chinese Medicine</orgName>
								<address>
									<addrLine>No.6 Community 1 Fangxingyuan</addrLine>
									<postCode>100071</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hu</forename><forename type="middle">K A</forename><surname>Multicenter</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Dongfang hospital</orgName>
								<orgName type="department" key="dep2">Fengtai District</orgName>
								<orgName type="institution">Beijing University of Chinese Medicine</orgName>
								<address>
									<addrLine>No.6 Community 1 Fangxingyuan</addrLine>
									<postCode>100071</postCode>
									<settlement>Beijing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1097/MD.0000000000021626</idno>
					<note type="submission">Received: 2 July 2020 / Accepted: 8 July 2020</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>chemotherapy</term>
					<term>cryoablation</term>
					<term>randomized controlled trial</term>
					<term>stage IIIB/IV non-small cell lung cancer</term>
					<term>traditional Chinese medicine formula</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Background: Chemotherapy is the main therapy for stage IIIB/IV non-small cell lung cancer (NSCLC). However, the 5-year survival rate is 6%. Cancer Green Therapy is a novel therapy in China, which refers to cryoablation combined with traditional Chinese medicine (TCM) formula. Our previous retrospective analysis showed that patients with NSCLC had longer survival time and better quality of life after receiving cryoablation combined with TCM formula, compared with patients who received chemotherapy alone. Methods: This study is a multicenter, randomized, controlled clinical study. The experiment will be carried out in 6 hospitals at the same time, and a total of 450 cases of participants will be randomly assigned to the experimental group and the control group (n = 225). The experimental group will be given cryoablation and 28-days TCM formula, and the control group will be given 4 cycles chemotherapy. After 30 months of follow-up, the efficacy and safety of cryoablation combines with TCM formula in patients with stage IIIB/IV NSCLC will be observed. The primary outcome is overall survival. The secondary outcomes include progression-free survival, objective response rate, and quality of life. We will also conduct a safety evaluation of the treatment at the end of the trial. Discussion: This multicenter, randomized, controlled clinical study not only provides data on the efficacy and safety of cryoablation combined with TCM formula, but also provides a novel treatment strategy for clinicians and advanced NSCLC patients. Abbreviations: CT = computed tomography, NSCLC = non-small cell lung cancer, ORR = objective remission rate, OS = overall survival, PFS = profession-free survival, QOL = quality of life, TCM = traditional Chinese medicine.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p>Lung cancer is the most common type of cancer and the leading cause of cancer death. <ref type="bibr" target="#b0">[1]</ref> Non-small cell lung cancer (NSCLC) accounts for 75% to80% of lung cancer, and the 5-year survival rate is about 15%. <ref type="bibr" target="#b1">[2]</ref> The main pathological types of NSCLC are adenocarcinoma (32% -40%), squamous cell carcinoma (25% -30%), and large cell carcinoma (8% -16%). <ref type="bibr" target="#b2">[3]</ref> About 70% of lung cancer patients are at an advanced stage when they are first diagnosed, and surgery therapy isn't available for which. Chemotherapy, radiotherapy, targeted therapy, and immunotherapy can be selected as treatments for stage IIIB/IV NSCLC, platinum-based doublets chemotherapy is the main option among which. However, the effective rate of each chemotherapy regimen varies from 20% to 30%, and progress-free survival (PFS) is only a few months. <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref> Also, adverse events such as marrow suppression, nausea, vomiting can decrease the quality of life (QOL) of patients. <ref type="bibr" target="#b6">[7]</ref> It is necessary to find an effective and safe treatment for advanced NSCLC.</p><p>Cryoablation is a novel surgical therapy for benign and malignant tumors, especially for unresectable tumors. It's a minimally invasive treatment in which the tumor is frozen and destroyed by cryoprobes, and the process lasts about 20 minutes. Therefore, cryoablation has the advantages of highly targeted, more repeatability, less trauma, and fewer side effects. <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref> It is widely used in liver cancer, kidney cancer, prostate cancer, and lung cancer. <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref> In a study, 50 patients with advanced lung cancer were treated with argon-helium knife ablation. The treatment effect was relatively ideal, with a median survival time of 19 months, a 1-year survival rate of 87.2%, and a 2-year survival rate of 22.4%. <ref type="bibr" target="#b14">[15]</ref> Some studies have suggested that argon-helium knife cryoablation is a better minimally invasive treatment for elderly lung cancer patients, which has a slight impact on the respiratory function of patients, prolong the survival time of patients, and improve the related symptoms caused by tumors. <ref type="bibr" target="#b15">[16]</ref> Traditional Chinese medicine (TCM) has certain advantages in the treatment of advanced NSCLC. When combined with chemotherapy and radiotherapy, it can enhance long-term efficiency and decrease side effects of them, such as bone marrow suppression, nausea, vomiting, and radioactive inflammation. In addition, TCM can promote postoperative recovery and prevent tumors' relapse and metastasis. <ref type="bibr" target="#b17">[17]</ref> As for those who can't receive surgical therapy, chemotherapy, and radiotherapy, TCM can improve clinical symptoms and the QOL of patients. What's more, many studies report that TCM can inhibit or stabilize the development of tumors, help patients achieve "survival with tumor" . <ref type="bibr" target="#b18">[18]</ref> However, many studies of TCM have problems with sample size and follow-up visits. Thus, they need to be further improved.</p><p>Initially, many elderly patients with advanced lung cancer chose Cancer Green Therapy (cryoablation combined with TCM) for better QOL. However, we found that the survival was longer than that we had expected during the follow-up visit. Later, we conducted a retrospective analysis and screened 186 patients who underwent cryoablation plus TCM in our department between 2005 and 2013. 119 cases were followed up in 2014. Among them, 82 cases were advanced NSCLC patients, the average overall survival (OS) of them is 18 months, almost double as that in NCCN guidelines (8-10 months). <ref type="bibr" target="#b19">[19,</ref><ref type="bibr" target="#b20">20]</ref> The present multi-center, prospective, randomized controlled trial is designed to investigate the efficacy and safety of Cancer Green Therapy (cryoablation combined with TCM), setting chemotherapy as the control treatment. We hope that, through this rigorously designed study, we can provide scientific and objective assessments for the efficacy and safety of cryoablation combined with TCM for stage IIIB/IV NSCLC patients and possibly offer the world an alternative treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Methods and design</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Study design</head><p>The trial is a multi-center, prospective, randomized controlled trial. The flowchart of the study is presented in <ref type="figure" target="#fig_1">Figure 1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Ethical issues</head><p>The clinical trial has been registered on the Chinese Clinical Trial Registry (ChiCTR1900027428). The study protocol (version 2.0 in December 2018) has been approved by the research ethics committee of Dongfang Hospital Beijing University of Chinese Medicine (JDF-IRB-2019030103). The research ethics committee will also be responsible for supervising all procedures of the study, including participant recruitment, randomization, conduction, and data storage. In case of any changes to the study protocol, we will submit a written application to the research ethics committee. They will decide whether it is acceptable to make the change.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Recruitment</head><p>A total of 450 eligible participants will be recruited from 6 hospitals in different parts of China: Dongfang Hospital, Beijing Hospital of Chinese medicine, China-Japan Friendship Hospital, Beijing Hospital, Longhua Hospital, and Hubei Hospital of Chinese Medicine. Both inpatients and outpatients will be screened for participation from March 2019.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Informed consent</head><p>Potentially eligible participants will be invited to take part in our study. Before enrollment, researchers will thoroughly introduce the detailed procedures of the study to the participants. All questions and concerns raised about the study will be addressed at length. Participants will also be informed of the probable benefits and potential risks and assured that participation is entirely voluntary. Participants who meet all the inclusion criteria and none of the exclusion criteria will be enrolled after providing written informed consent. The personal information of all the participants will always be kept confidential. 2.5.2. Exclusion criteria. Participants meeting any 1 of the exclusion criteria will not be enrolled:</p><p>(1) Radiation therapy, chemotherapy, targeted therapy or immunotherapy within a month; (2) Brain metastases;</p><p>(3) Inflammation around the lesion, or skin infection and ulceration at the puncture site; (4) Severe pulmonary fibrosis; (5) Severe bleeding tendency, platelet count &lt; 50 Â 10 9 /L and severe coagulation disorders; (6) Malignant pleural effusion; (7) Pregnant and lactating women; severe dysfunction of liver, kidney, heart, lung; severe anemia, electrolyte disturbance, and malnutrition; severe systemic infection and high fever (T &gt; 38.5°C); (8) HIV antibody positive; immunodeficiency diseases; (9) History of organ transplantation; (10) Enrolled in other clinical trials within 3 months.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6.">Randomization and allocation concealment</head><p>The participants will be randomized at 1:1 (225 in each group) by researchers in Peking University clinical research institute (PUCRI). The Red Cap system of PUCRI will generate random allocation sequences based on the basic information (name, age, gender) of participants and feed back to researchers in the participating centers through the network.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7.">Blind</head><p>In this study, researchers and patients will not be blinded due to the different treatment regimens. However, evaluators and statistical analysts will be blind to patient enrollment and treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8.">Interventions</head><p>Participants allocated to the study group will receive cryoablation and TCM syndrome differentiation and treatment, while chemotherapy will be applied in the control group.</p><p>Cryoablation therapy will refer to Expert Consensus for Thermal Ablation for Primary and Metastatic Lung Tumors (2017 Edition). <ref type="bibr" target="#b21">[21]</ref> Cryoablation will start in 2 weeks of randomization. TCM syndrome differentiation and treatment will be based on guidelines in the TCM Diagnosis and Treatment Scheme for Lung Cancer (2017) ( <ref type="table" target="#tab_0">Table 1)</ref>. TCM formula will be made into watersoluble granules. Patients will dissolve them with warm water for a drink in the morning and evening for 28 days after cryoablation.</p><p>Participants in control group will receive 1 of following 5 platinum-based chemotherapy regimens. Each chemotherapy cycle has 3 weeks, lasting 4 to 6 cycles. Any questions raised by the participants will be answered to promote completion. The detailed study schedule is listed in <ref type="table">Table 2</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.9.">Outcome measurements</head><p>Outcome measurements are scheduled at screening, baseline, and every visit. 2.9.1. Basic characteristic variables. Basic data of all the participants, including name, gender, date of birth, marital status, educational level, date of diagnosis, and medical history, will be collected. General physical examination results, including vital signs (body temperature, blood pressure, respiratory rate, and heart rate), will also be recorded. Concomitant medication will be inquired about and documented at every visit. In the follow-up period, enhanced computed tomography (CT) of chest and tumor marks will be inspected every 3 months until the deadline of the trial or death. Magnetic resonance imaging, ultrasound, bone scans, and CT scans of other parts will be inspected to assess metastasis by researchers.</p><p>2.9.2. Primary outcome. The OS: Time from randomization to death for any reason. If the participants will be lost to follow-up or alive at the end of the study, the last follow-up time will be used as the death time.</p><p>2.9.3. Secondary outcomes.</p><p>(1) Progression-free survival: Time from the randomization to tumor progression or death. PFS rates of 6 months and 1 year will also be calculated.</p><p>(2) Objective remission rate (ORR): Enhanced CT of the chest will be performed at the baseline period and the end of therapy. The therapeutic effect will be evaluated as complete response (CR), partial response (PR), stability disease (SD), and progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST). ORR will be defined as the percentage of CR and PR cases in patients. (3) QOL: QOL will refer to the European Organization for Research and Treatment of Cancer Quality Life Questionnaire Core 30 scale and lung cancer-specific LC13 scale.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.10.">Safety assessments</head><p>Safety outcomes involve blood, urine and stool analysis, hepatic and renal function, electrolyte levels, coagulation function, Creaction protein, and electrocardiogram. Safety outcomes will be assessed at each cycle visit.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.11.">Quality control</head><p>Before the conduction of the protocol, a range of training will be provided to all the researchers, ensuring a full understanding and mastery of the standard operating procedures. Any change to the <ref type="table">Table 2</ref> Data collection schedule.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cryoablation plus TCM Chemotherapy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characteristic</head><p>Baseline period 7d before therapy starts</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7">d after cryoablation</head><p>The end of TCM therapy</p><p>The end of cycle 1</p><p>The end of cycle 2</p><p>The end of cycle 3</p><p>The end of cycle 4</p><p>Written informed consent/checking inclusion and exclusion criteria X CT scan of chest will be inspected every 3 months, ultrasound, MRI and bone scintigraphy of other parts will be performed according clinical indication.</p><formula xml:id="formula_0">Demographics X Medical history X Concomitant medication X X X X X X X Physical examination X X X X X X X Vital signs X X X X X X X ECOG PS X X X X X X X TCM symptoms X X X X X X X EORTC QLQ-C30 and LC13 X X X X X X X CT scans of chest X X X X CT or MRI of upper abdomen X X X X CT or MRI of brain X X X X Bone scintigraphy X Abdominal ultrasound X Heart ultrasound X Pulmonary function test X Electrocardiogram X X X X X X X Tumor markers X X X X Routine blood analysis X X X X X X X Routine urine analysis X X X X X X X Routine stool analysis X X X X X X X Laboratory hepatic analysis X X X X X X X Laboratory renal analysis X X X X X X X Laboratory electrolyte analysis X X X X X X X C-reaction protein X X X X X X X Coagulation function analysis X X X X X X X Blood gas analysis X Adverse events X X X X X X Therapeutic effect X X X Follow-</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sun et al. Medicine (2020) 99:33</head><p>Medicine protocol should be reported in writing to the primary researcher in Dongfang Hospital and can be applied only after permission. The quality of CRFs will be regularly supervised by independent investigators in Dongfang Hospital. Researchers will be notified in a timely fashion if any error exists.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.12.">Sample size calculation</head><p>Two-sided, log-rank test of Kaplan-Meier survival analysis is used to calculate the sample size. The primary outcome is the OS. The sample size is calculated based on the primary outcome. According to the data of NCCN guidelines and previous study, the median OS is 10 months in the control group and 14 months in the study group. With an estimated 18 months of enrollment and 30 months of follow-up, we have calculated that 402 patients will be needed to show a 2-sided significance level of 5% and a statistical power of 80%. Allowing for a 10% dropout rate, the sample size has been set at 450 patients (225 in each group).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.13.">Data management and analysis</head><p>CRFs will be entered by 2 independent researchers and supervised by a third 1 to ensure accuracy. Data analysis will be performed by statisticians who are blind to the randomization by using SAS9.3 software (Software security authorization No. 11202165). A significance level of 0.05 will be adopted throughout the trial. The primary outcome of the study is OS, with secondary outcomes including PFS, ORR, the incidence of adverse events, and results of a QOL survey. OS curves will be estimated for each treatment group in the full analysis set using the Kaplan-Meier method. Median OS and 95% CIs will be calculated. To evaluate differences in therapeutic effects, the HRs of the 2 groups and their 95% CIs will be calculated using the Cox proportional hazard model with adjustment factors, except for institution, included as covariates.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.14.">Ethics and dissemination</head><p>Central ethical approval has been confirmed from the research ethics committee of Dongfang Hospital Beijing University of Chinese Medicine (JDF-IRB-2019030103). Local ethical approval from other participating hospitals has also been obtained. The study will be conducted under the principles of the Declaration of Helsinki. The trial organization, data management, monitoring, and reporting will also be conducted under the guidelines for Good Clinical Practice and other regulations. Patients will be given full and adequate oral and written information about the study. The consent will be provided by the patient or a legally authorized representative.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Discussion</head><p>The treatment of cryoablation combined with TCM is welcomed among advanced patients in China because of the QOL. Although some studies have reported the efficiency of cryoablation combined with TCM, high-quality evidence is poor. The trial protocol is based on Standard Protocol Items: Recommendations for Interventional Trials guidelines. It has a high-quality methodology to prove whether cryoablation plus TCM has higher OS. We except that the treatment could be a better option for stage IIIB/IV NSCLC patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Trial status</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>1 .( 1 )</head><label>11</label><figDesc>Inclusion criteria. Participants meeting all the following criteria will be enrolled: Histologically or cytologically confirmed NSCLC and clinical-stage IIIB or IV; (2) Conform to TCM syndrome differentiation; (2) Lesion ≥ 2 cm in diameter; (3) Eastern Cooperative Oncology Group score 2; (4) Expected survival ≥ 3 months; (5) Age ≥ 18; (6) Participate the trial voluntarily and sign written informed consent.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc>Overview of the Study Design. AEs = adverse events, ECOG = Eastern Cooperative Oncology Group, NSCLC = non-small cell lung cancer, ORR = objective remission rate, OS = overall survival, PFS = profession-free survival, PS = performance status, QOL = quality of life, TCM = traditional Chinese medicine. Sun et al. Medicine (2020) 99:33 Medicine</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>( 1 )</head><label>1</label><figDesc>NP regimen: vinorelbine 25 mg/m 2 on days 1 and 8 and cisplatin 75 mg/m 2 on day 1; (2) GP regimen: gemcitabine 1250 mg/m 2 on days 1 and 8, and cisplatin 75 mg/m 2 on day 1; (3) TC regimen: paclitaxel 200 mg/m 2 on day 1, and carboplatin area under the curve 6 on day 1; (4) DP regimen: docetaxel 75 mg/m 2 on day 1, and cisplatin 75 mg/m 2 on day 1.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc>up assessment * CT = compute tomography, ECOG = Easter Cooperative Oncology Group, EORTC = European Organization for Research and Treatment Cancer, MRI = magnetic resonance imaging, PS = performance status, QLQ-C30 = quality life questionnaire core 30, QLQ-LC13 = quality of life questionnaire-lung cancer-specific module 13, TCM = traditional Chinese medicine. *</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 TCM</head><label>1</label><figDesc>Syndrome Differentiation and Treatment.</figDesc><table><row><cell>TCM syndrome differentiation</cell><cell>Symptoms</cell><cell>TCM treatment</cell></row><row><cell></cell><cell></cell><cell>Modified sha shen mai men dong tang: raw Astragalus 30g, Radix</cell></row><row><cell></cell><cell></cell><cell>Glehniae 15g, Liriope 12g, Trichosanthin 12g, Honeysuckle 30g,</cell></row><row><cell></cell><cell></cell><cell>Angelica Sinensis 12g, Glycyrrhiza Uralensis 9g, Bee cell 5g,</cell></row><row><cell></cell><cell></cell><cell>Centipede 3g;</cell></row><row><cell>Lung and spleen qi</cell><cell>Main symptoms: chronic cough, big amount of sputum, chest</cell><cell>Modified liu jun zi tang: raw Astragalus 30g, Lanceolata 15g,</cell></row><row><cell>deficiency syndrome</cell><cell>distress, shortness of breath, fatigue.</cell><cell>Atractylodes 15g, Poria Cocos 12g, Pinellia Ternata 12g,</cell></row><row><cell></cell><cell>Secondary symptoms: abdominal distension, anorexia,</cell><cell>Tangerine Peel 12g, Trichosanthin 12g, Honeysuckle 30g,</cell></row><row><cell></cell><cell>edema, loose stool, pale tongue with thin coating and teeth</cell><cell>Angelica Sinensis 30g, Liriope 12g, Glycyrrhiza Uralensis 9g, Bee</cell></row><row><cell></cell><cell>marks, deep and thin pulse.</cell><cell>cell 5g, Centipede 3g;</cell></row><row><cell>Lung yin deficiency syndrome</cell><cell>Main symptoms: cough, small amount of sputum, afternoon</cell><cell>Modified mai wei di huang tang: Liriope 30g, Prepared Radix</cell></row><row><cell></cell><cell>tidal fever, night sweat, burning sensation of five centers.</cell><cell>Rehmanniae 30g, Chinese Yam 20g, Cornus officinalis Sieb 20g,</cell></row><row><cell></cell><cell>Secondary symptoms: dry mouth, thirst, hoarseness, bright</cell><cell>Cortex Moutan 12g, Poria Cocos 12g, Alisma Orientale 12g, raw</cell></row><row><cell></cell><cell>red tongue with less coating or thin tongue body with thin</cell><cell>Astragalus 30g, Trichosanthin 10g, Honeysuckle 30g, Schisandra</cell></row><row><cell></cell><cell>coating, rapid string pulse.</cell><cell>Chinensis 3g, Angelica Sinensis 12g, Glycyrrhiza Uralensis 9g,</cell></row><row><cell></cell><cell></cell><cell>Bee cell 5g, Centipede 3g;</cell></row><row><cell>Qi stagnation and</cell><cell>Main symptoms: cough, shortness of breath, chest distress,</cell><cell>Modified si wu tang: Angelica Sinensis 30g, Red peony root 15g,</cell></row><row><cell>blood stasis syndrome</cell><cell>pricking or swelling pain of heart and chest.</cell><cell>Ligusticum Wallichii 12g, Prepared Radix Rehmanniae 30g, raw</cell></row><row><cell></cell><cell>Secondary symptoms: pain aggravated by touching abdominal</cell><cell>Astragalus 30g, Trichosanthin 12g, Honeysuckle 30g, Liriope 12g,</cell></row><row><cell></cell><cell>mass, dark lips, purple dark tongue with spot of blood stasis</cell><cell>Glycyrrhiza Uralensis 9g, Bee cell 5g, Centipede 3g;</cell></row><row><cell></cell><cell>and thin coating, string or astringent pulse.</cell><cell></cell></row><row><cell>Retention of phlegm-heat</cell><cell></cell><cell></cell></row><row><cell>in the lung syndrome</cell><cell></cell><cell></cell></row></table><note>Qi-yin deficiency syndrome Main symptoms: cough, small amount of phlegm, fatigue, shortness of breath, dry mouth. Secondary symptoms: sweating, afternoon tidal fever, feverishness in palms and soles, palpitations, reddish tongue with thin coating or fat tongue with teeth marks, fine pulse.Main symptoms: severe cough, big amount of yellow and thick phlegm, breathlessness, chest distress. Secondary symptoms: fever, anorexia, bright red tongue with yellow thick greasy coating, taut, slippery and rapid pulse. Modified er chen tang: Tangerine Peel 12g, Pinellia Ternata 12g, Poria Cocos 12g, Trichosanthes Kirilowii Maxim 15g, Scutellaria 9g, Fritillaria Thunbergii 15g, raw Astragalus 30g, Trichosanthin 12g, Honeysuckle 30g, Angelica Sinensis 12g, Liriope 12g, Glycyrrhiza Uralensis 9g, Bee cell 5g, Centipede 3g.TCM = traditional Chinese medicine.</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Recruitment started in March 2019, and it is expected to finish in December 2021.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The authors have no conflicts of interest to disclose.</p><p>The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p>We appreciate the efforts of all research staff participating in this trial. We also acknowledge the helpful support of all participants. The results of this clinical trial will be published in the form of academic articles by our research team. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author contributions</head></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Bray</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Soerjomataram</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA: a cancer journal for clinicians</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="394" to="424" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Non-small-cell lung cancers: a heterogeneous set of diseases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Fillmore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">S</forename><surname>Hammerman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="535" to="581" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Treatment of nonsmall cell lung cancer (NSCLC)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Zarogoulidis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Zarogoulidis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Darwiche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Dis</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="389" to="396" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Fossella</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Von</forename><surname>Pawel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="3016" to="3040" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">V</forename><surname>Scagliotti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">De</forename><surname>Marinis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Rinaldi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="4285" to="91" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Schiller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Harrington</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">P</forename><surname>Belani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="92" to="100" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">D</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">Y</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Drug Targets</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="67" to="73" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">How I do it: radiofrequency ablation and cryoablation of lung tumors</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Lanuti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Imaging</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="162" to="74" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The application of cryosurgery in the treatment of lung cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">O</forename><surname>Maiwand</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">E</forename><surname>Beeson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cryobiology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="55" to="61" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Update on cryotherapy for prostate cancer in 2006</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Mouraviev</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Polascik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Urol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="152" to="158" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">C</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">Z</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">B</forename><surname>He</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="2686" to="2695" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Percutaneous cryoablation for stage IV lung cancer: a retrospective analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Yao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cryobiology</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="151" to="156" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Cryotherapy protocols for metastatic breast cancer after failure of radical surgery</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cryobiology</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="17" to="22" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Cryoablation for renal tumors: current status</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kamoi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">S</forename><surname>Gill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Urol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="138" to="180" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kongnyuy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">E</forename><surname>Kosinski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Hyperthermia</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="810" to="813" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Recent perspectives of management of breast cancer metastasis -an update</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Tian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Guo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of B.U. ON: official journal of the Balkan Union of Oncology</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="295" to="300" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Sun</surname></persName>
		</author>
		<ptr target="33www.md-journal.com" />
		<imprint>
			<date type="published" when="2020" />
			<biblScope unit="page">99</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: a randomized controlled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">P</forename><surname>Shen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Complement Ther Med</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="55" to="62" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The possibility of traditional chinese medicine as maintenance therapy for advanced nonsmall cell lung cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Evid Based Complement Alternat Med</title>
		<imprint>
			<biblScope unit="page">278917</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Combined therapy of percutaneous cryoablation and traditional Chinese medicine can be a promising strategy for elderly or advanced lung cancer patients based on a retrospective clinical study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Jiang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cryobiology</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="174" to="181" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">NCCN guidelines insights: nonsmall cell lung cancer, Version 5</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Ettinger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Aisner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">E</forename><surname>Wood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Compr Canc Netw</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="807" to="828" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Expert consensus for thermal ablation for primary and metastatic lung tumors</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Xin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fan</forename><surname>Weijun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wang</forename><surname>Hui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Zhong Guo Fei Ai Za Zhi</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="433" to="478" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
	<note>Edition</note>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Sun</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2020" />
			<biblScope unit="page">33</biblScope>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
